Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.

Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF.

Eur J Neurol. 2014 Jun;21(6):851-9. doi: 10.1111/ene.12393. Epub 2014 Mar 15.

2.

Apparent life-threatening events: difficult for parents, difficult for clinicians.

Winckworth LC, Earl NL, Stewart C.

Arch Dis Child. 2013 Jun;98(6):479. doi: 10.1136/archdischild-2013-303746. Epub 2013 Apr 4. No abstract available.

PMID:
23559601
3.

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Hersh BP, Earl NL, Hauser RA, Stacy M.

Mov Disord. 2010 May 15;25(7):927-31. doi: 10.1002/mds.23040.

PMID:
20461810
4.

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; 228 Study Investigators.

Mov Disord. 2010 May 15;25(7):858-66. doi: 10.1002/mds.22890.

PMID:
20461803
5.

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL; EASE-PD Adjunct Study Investigators.

Neurology. 2007 Apr 3;68(14):1108-15.

PMID:
17404192
6.

A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group.

Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET.

J Clin Psychiatry. 2000 Nov;61(11):841-50.

PMID:
11105737
7.

Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group.

Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM.

Neurology. 1997 Nov;49(5):1219-25.

PMID:
9371897
8.
9.

Sudden unexplained death in epilepsy: observations from a large clinical development program.

Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder P, Siscovick D, Wannamaker BB, Tennis PS, Cierpial MA, Earl NL.

Epilepsia. 1997 Jan;38(1):47-55.

10.
11.

Neural correlates of dementia: regional brain metabolism (FDG-PET) and the CERAD neuropsychological battery.

Welsh KA, Hoffman JM, Earl NL, Hanson MW.

Arch Clin Neuropsychol. 1994 Oct;9(5):395-409.

PMID:
14589655
12.

Adult onset Niemann-Pick disease type C presenting with dementia and absent organomegaly.

Hulette CM, Earl NL, Anthony DC, Crain BJ.

Clin Neuropathol. 1992 Nov-Dec;11(6):293-7.

PMID:
1473312
13.

Evaluation of cerebral biopsies for the diagnosis of dementia.

Hulette CM, Earl NL, Crain BJ.

Arch Neurol. 1992 Jan;49(1):28-31.

PMID:
1728259
14.

Ratings of personality change in patients being evaluated for memory disorders.

Siegler IC, Welsh KA, Dawson DV, Fillenbaum GG, Earl NL, Kaplan EB, Clark CM.

Alzheimer Dis Assoc Disord. 1991 Winter;5(4):240-50.

PMID:
1781966
15.

Sib-pair linkage analysis in late onset Alzheimer's disease.

Dawson DV, Roses AD, Pericak-Vance MA, Kaplan EB, Elston RC, Haynes CS, Gaskell PC Jr, Heyman A, Clark CM, Earl NL.

Prog Clin Biol Res. 1989;317:223-8. No abstract available.

PMID:
2602418

Supplemental Content

Support Center